Development of an intensified fed-batch production platform with doubled titers using N-1 perfusion seed for cell culture manufacturing

Abstract

The goal of cell culture process intensification is to increase volumetric productivity, generally by increasing viable cell density (VCD), cell specific productivity or production bioreactor utilization in manufacturing. In our previous study, process intensification in fed-batch production with higher titer or shorter duration was demonstrated by increasing the inoculation seeding density (SD) from ~ 0.6 (Process A) to 3–6 × 10⁶ cells/mL (Process B) in combination with media enrichment. In this study, we further increased SD to 10–20 × 10⁶ cells/mL (Process C) using perfusion N-1 seed cultures, which increased titers already at industrially relevant levels by 100% in 10–14 day bioreactor durations for four different mAb-expressing CHO cell lines. Redesigned basal and feed media were critical for maintaining higher VCD and cell specific productivity during the entire production duration, while medium enrichment, feeding strategies and temperature shift optimization to accommodate high VCDs were also important. The intensified Process C was successfully scaled up in 500-L bioreactors for 3 of the 4 mAbs, and quality attributes were similar to the corresponding Process A or Process B at 1000-L scale. The fed-batch process intensification strategies developed in this study could be applied for manufacturing of other mAbs using CHO and other host cells.

Keywords

Fed-batch platform / Process intensification / Monoclonal antibody manufacturing / Perfusion N-1 / Chinese hamster ovary cells

References

[1] Bausch M, Schultheiss C, Sieck JB. Recommendations for comparison of productivity between fed-batch and perfusion processes. Biotechnol J, 2019

[2] Bechmann J, Greulich B, Mueller MM, Schulz P, Wucherpfennig T, Bradl H. Platform approach speeds process development. BioPharm Int, 2016, 29(4): 20-25.

[3] Bielser JM, Wolf M, Souquet J, Broly H, Morbidelli M. Perfusion mammalian cell culture for recombinant protein manufacturing—a critical review. Biotechnol Adv, 2018, 36(4): 1328-1340.

[4] Chen C, Wong HE, Goudar CT. Upstream process intensification and continuous manufacturing. Curr Opin Chem Eng, 2018, 22: 191-198.

[5] Croughan MS, Konstantinov KB, Cooney C. The future of industrial bioprocessing: batch or continuous?. Biotechnol Bioeng, 2015, 112(4): 648-651.

[6] Du C, Xu J, Song H, Tao L, Lewandowski A, Ghose S, Borys M, Li Z. Mechanisms of color formation in drug substance and mitigation strategies for the manufacture and storage of therapeutic proteins produced using mammalian cell culture. Process Biochem, 2019, 86: 127-135.

[7] Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs, 2015, 7(1): 9-14.

[8] Galbraith SC, Bhatia H, Liu H, Yoon S. Media formulation optimization: current and future opportunities. Curr Opin Chem Eng, 2018, 22: 42-47.

[9] Gallo-Ramírez LE, Nikolay A, Genzel Y, Reichl U. Bioreactor concepts for cell culture-based viral vaccine production. Expert Rev Vaccines, 2015, 14(9): 1181-1195.

[10] Handlogten MW, Lee-O’Brien A, Roy G, Levitskaya SV, Venkat R, Singh S, Ahuja S. Intracellular response to process optimization and impact on productivity and product aggregates for a high-titer CHO cell process. Biotechnol Bioeng, 2018, 115(1): 126-138.

[11] Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol, 2014, 32(1): 40-51.

[12] Huang YM, Hu W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol Prog, 2010, 26(5): 1400-1410.

[13] Jordan M, Mac Kinnon N, Monchois V, Stettler M, Broly H. Intensification of large-scale cell culture processes. Curr Opin Chem Eng, 2018, 22: 253-257.

[14] Kaplon H, Reichert JM. Antibodies to watch in 2019. mAbs, 2019, 11(2): 219-238.

[15] Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs, 2009, 1(5): 440-449.

[16] Kelley B, Kiss R, Laird M (2018) A different perspective: how much innovation is really needed for monoclonal antibody production using mammalian cell technology? In: Advances in biochemical engineering/biotechnology. vol 165. Springer Science and Business Media Deutschland GmbH, pp 443–462

[17] Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol, 2016, 100(8): 3451-3461.

[18] Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. mAbs, 2010, 2(5): 466-477.

[19] Lin PC, Chan KF, Kiess IA, Tan J, Shahreel W, Wong SY, Song Z. Attenuated glutamine synthetase as a selection marker in CHO cells to efficiently isolate highly productive stable cells for the production of antibodies and other biologics. mAbs, 2019, 11(5): 965-976.

[20] Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci, 2020

[21] McHugh KP, Xu J, Aron KL, Borys MC, Li ZJ. Effective temperature shift strategy development and scale confirmation for simultaneous optimization of protein productivity and quality in Chinese hamster ovary cells. Biotechnol Prog, 2020 In press)

[22] Mir-Artigues P, Twyman RM, Alvarez D, Cerda Bennasser P, Balcells M, Christou P, Capell T. A simplified techno-economic model for the molecular pharming of antibodies. Biotechnol Bioeng, 2019, 116(10): 2526-2539.

[23] Moulijn JA, Stankiewicz A. Process intensification. Encyclopedia of sustainable technologies, 2017, Amsterdam: Elsevier, 509-518.

[24] Padawer I, Ling WLW, Bai Y. Case study: an accelerated 8-day monoclonal antibody production process based on high seeding densities. Biotechnol Prog, 2013, 29(3): 829-832.

[25] Pohlscheidt M, Jacobs M, Wolf S, Thiele J, Jockwer A, Gabelsberger J, Jenzsch M, Tebbe H, Burg J. Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors. Biotechnol Prog, 2013, 29(1): 222-229.

[26] Rader RA, Langer ES (2015) 30 years of upstream productivity improvements. BioProcess Int 13(2). https://bioprocessintl.com/upstream-processing/expression-platforms/30-years-upstream-productivity-improvements/

[27] Stankiewicz AI, Moulijn JA. Process intensification: transforming chemical engineering. Chem Eng Prog, 2000, 96(1): 22-33.

[28] Takagi Y, Kikuchi T, Wada R, Omasa T. The enhancement of antibody concentration and achievement of high cell density CHO cell cultivation by adding nucleoside. Cytotechnology, 2017, 69(3): 511-521.

[29] Tang P, Xu J, Louey A, Tan Z, Yongky A, Liang S, Li Z, Weng Y, Liu S. Kinetic modeling of Chinese hamster ovary cell culture: factors and principles. Crit Rev Biotechnol, 2020, 40(2): 265-281.

[30] Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol, 2018, 36(12): 1136-1145.

[31] Warikoo V, Godawat R, Brower K, Jain S, Cummings D, Simons E, Johnson T, Walther J, Yu M, Wright B, McLarty J, Karey KP, Hwang C, Zhou W, Riske F, Konstantinov K. Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng, 2012, 109(12): 3018-3029.

[32] Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol, 2004, 22(11): 1393-1398.

[33] Wurm FM. CHO Quasispecies—implications for manufacturing processes. Processes, 2013, 1: 296-311.

[34] Xu J, Rehmann MS, Xu X, Huang C, Tian J, Qian NX, Li ZJ. Improving titer while maintaining quality of final formulated drug substance via optimization of CHO cell culture conditions in low-iron chemically defined media. mAbs, 2018, 10(3): 488-499.

[35] Xu J, Tang P, Yongky A, Drew B, Borys MC, Liu S, Li ZJ. Systematic development of temperature shift strategies for Chinese hamster ovary cells based on short duration cultures and kinetic modeling. mAbs, 2019, 11(1): 191-204.

[36] Yang WC, Lu J, Kwiatkowski C, Yuan H, Kshirsagar R, Ryll T, Huang YM. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. Biotechnol Prog, 2014, 30(3): 616-625.

[37] Yongky A, Xu J, Tian J, Oliveira C, Zhao J, McFarland K, Borys M, Li Z. Process intensification in fed-batch production bioreactors using non-perfusion seed cultures. mAbs, 2019, 11(8): 1502-1514.

[38] Yoon SK, Kim SH, Lee GM. Effect of low culture temperature on specific productivity and transcription level of anti-4-1BB antibody in recombinant Chinese hamster ovary cells. Biotechnol Prog, 2003, 19(4): 1383-1386.